Biorez Hosts Grand Opening Celebration at District in New Haven
Connecticut-Based Medical Startup Officially Moves into New Office and R&D Space
DECEMBER 19, 2018
Biorez Inc., an early-stage regenerative medicine company, has officially opened the company’s new office and R&D space, located at District in New Haven, and celebrated on Monday, December 3, with a gathering of employees, directors, investors, advisers and friends. The grand opening event included a reception and tour of the facility, with remarks from Biorez CEO Kevin Rocco and Biorez advisers Dr. Robert Stanton, of the Orthopaedic Specialty Group, and David Hook, formerly the Director of Market Development at Rotation Medical.
Biorez is focused on developing and commercializing regenerative implants related to the orthopedic surgery market. The company was named last month by U.S. Senator Chris Murphy as a “Murphy’s Innovator of the Month” and earlier this year raised $1.5 million in financing in a round led by Connecticut Innovations with participation from New York Angels, Pritzker-Vlock Family Office and The Vertical Group.
“We are excited to open our new office and lab space here at District in New Haven,” said Rocco, who expressed his gratitude to all attendees for their support and shared a brief update about the company’s recent progress. “This expands our R&D capabilities, sustains our growth and enables us to better develop and commercialize our proprietary regenerative technologies.”
Dr. Stanton shared his enthusiasm regarding the company’s mission and progress in developing regenerative technologies for sports medicine, calling it the “holy grail” of orthopedic surgery. Mr. Hook shared his support and belief in the promise of Biorez’s technology and his personal experience commercializing Rotation Medical’s rotator cuff device, before exiting to Smith & Nephew in 2017.
“District was created to help make Connecticut more connected and competitive so the state can attract and retain more innovative entrepreneurs, startup and scale-up businesses, like Biorez,” said David Salinas, District CEO. “The Biorez team is exactly the type of company we want in the ecosystem, and we are very happy they now call District their home.”
Current Biorez programs are focused on a bio-inductive scaffold for ACL reconstruction that spares harvesting of patient donor-tissue (autograft) and provides a more attractive alternative to cadaver (allograft) options. The company is developing a pipeline of devices for commercialization as early as 2020.
Biorez Appoints Jeff Grebner as Director of Clinical AffairsNOVEMBER 01, 2021
Biorez™ Raises $3.5 Million to Close Out $7 Million in Seed FinancingSEPTEMBER 09, 2020